Strategic Partnerships Radiopharm's collaboration with Siemens Healthineers to support a U.S. registrational program demonstrates a proven path to scale manufacturing and distribution for radiopharmaceuticals. This creates sales opportunities with large hospital systems, radiology departments, and contract manufacturers seeking reliable supply of imaging and therapeutic agents.

Clinical Momentum Active data generation and conference engagement indicate growing interest in Radiopharm's HER2-targeted theranostics, with HEAT trial data and AACR presentations supporting outreach to oncology centers and imaging facilities looking to adopt new diagnostic and therapeutic radiopharmaceuticals.

Growth and Governance Recent financing and leadership additions suggest an expanded commercialization plan, creating opportunities to discuss strategic collaborations, licensing, and regional market access deals with distributors, CROs, and service providers to accelerate adoption.

US Market Readiness With a path toward U.S. trials and an established supply partner, Radiopharm is well positioned to engage U.S. hospital networks, cancer centers, and radiopharmacies for product access, distribution agreements, and regulatory support services.

Theranostics Platform The dual diagnostic and therapeutic radiopharmaceutical platform, including the first-in-class HER2-targeted RAD202, offers multi-application opportunities across imaging and treatment. Focus sales efforts on imaging centers, nuclear medicine departments, and oncology clinics seeking bundled theranostics solutions.